KANGSTEM BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,610 KRW | -1.51% |
|
0.00% | +8.98% |
| 2023 | Kangstem Biotech Co., Ltd.(KOSDAQ:A217730) dropped from S&P Global BMI Index | CI |
| 2023 | Kang Stem Biotech to Raise 35.1 Billion Won via Shares Issuance; Shares Plunge 30% | MT |
| Sales 2022 | 16.3B 11.87M | Sales 2023 | 12.7B 9.25M | Capitalization | 134B 97.53M |
|---|---|---|---|---|---|
| Net income 2022 | -20.24B -14.73M | Net income 2023 | -21.95B -15.98M | EV / Sales 2022 | 5.31 x |
| Net cash position 2022 | 23.31B 16.97M | Net cash position 2023 | 23.75B 17.29M | EV / Sales 2023 | 8.68 x |
| P/E ratio 2022 |
-5.43
x | P/E ratio 2023 |
-4.43
x | Employees | 115 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.51% | ||
| Current month | +39.27% | ||
| 1 month | +38.10% | ||
| 3 months | +33.23% | ||
| 6 months | +70.59% | ||
| Current year | +8.98% |
1 week
2 245.00
2 860.00
1 month
1 835.003 050.00
Current year
1 713.003 050.00
1 year
1 166.003 485.00
3 years
1 166.007 400.00
5 years
1 166.0021 950.00
10 years
1 166.0024 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Cheon Na
CEO | Chief Executive Officer | 61 | - |
Seung-Hee Lee
CTO | Chief Tech/Sci/R&D Officer | 43 | - |
Seung-Won Im
AUD | Comptroller/Controller/Auditor | 64 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong-Ho Park
BRD | Director/Board Member | 68 | - |
Jung-Ho Choi
BRD | Director/Board Member | 63 | - |
Sang-Kyun Lee
BRD | Director/Board Member | 71 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 2,610 | -1.51% | 2,820,338 |
| 24-04-18 | 2,650 | +14.72% | 2,552,396 |
| 24-04-17 | 2,310 | 0.00% | 764,029 |
| 24-04-16 | 2,310 | -1.07% | 577,103 |
| 24-04-15 | 2,335 | -8.97% | 1,011,604 |
End-of-day quote Korea S.E., April 18, 2024
More quotes
Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohnâs disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.98% | 108M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- A217730 Stock
